The Government of Aragon on 18 October 2026 published the latest available figures for its breast cancer early detection programme for 2025. According to the figures, 72.3 per cent of women invited took part, exceeding by 2.3 percentage points the 70 per cent benchmark in the European Guidelines for Quality Assurance. The announcement was made in connection with the Día Mundial contra el Cáncer de Mama.
According to Departamento de Sanidad a total of 76,995 invitations were sent in 2025 to women aged 50 to 69; 55,695 mammograms were carried out. There were regional differences: Teruel reached 84.4 per cent, Huesca 75.6 per cent and Zaragoza 70.0 per cent. Teruel and Huesca were therefore well above the benchmark, while Zaragoza matched the EU figure exactly. According to the health administration, 73 per cent of tumours detected through the programme were diagnosed at an early stage.
Screening in Aragón is organised on a population basis, with personal invitations every two years giving the date, time and location of the examination. The administration notes that participation of at least 70 per cent is regarded as the threshold at which population-wide programmes can demonstrably reduce mortality and disease burden. Higher participation rates increase the chance of detecting tumours at an early, treatable stage. However, whether and to what extent this affects mortality and quality of life in Aragón requires ongoing evaluation across several cohorts.
Background and context: The European Guidelines for Quality Assurance recommend 70 per cent participation as a benchmark for quality-assured programmes. Regional differences have been observed in Aragón for years, prompting responses in the form of information campaigns and targeted outreach in primary healthcare areas. The annual figures come from routine reporting by the Gobierno de Aragón and are compiled at regular intervals. Additional indicators – such as abnormality rates, further diagnostic procedures and intervals before follow-up – are part of the official statistics and feed into the quality assessment.
Facts and attributions: The rates, absolute figures and provincial data given here are based on figures published by the Departamento de Sanidad on 18 October 2026, relating to the 2025 calendar year. Statements about the benefits of early detection are attributed to the health administration. No forecasts are made about long-term effects on mortality; these require detailed analyses over several years.
Editor: Clara Simonichek (Article created with AI assistance).